Corvus Pharmaceuticals(CRVS) - 2025 Q1 - Quarterly Results

EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders provid ...